Whitehawk Expands Cancer Pipeline with New Deal

Whitehawk Therapeutics just signed a deal with Hangzhou DAC to expand its cancer treatment pipeline. They're planning to use a technology called CPT113 in up to five new drug programs, which could mean some serious progress in cancer therapies. Whitehawk is also ramping up trials for its current treatments, with results expected in 2027. What does it mean for you? If you're keeping an eye on cancer treatments, this means there might be new, potentially better options coming your way in the next few years. Keep your fingers crossed for some groundbreaking news.